Cargando…

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models

OBJECTIVES: Following a maintenance course of rituximab (RTX) for ANCA-associated vasculitis (AAV), relapses occur on cessation of therapy, and further dosing is considered. This study aimed to develop relapse and infection risk prediction models to help guide decision making regarding extended RTX...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClure, Mark E, Zhu, Yajing, Smith, Rona M, Gopaluni, Seerapani, Tieu, Joanna, Pope, Tasneem, Kristensen, Karl Emil, Jayne, David R W, Barrett, Jessica, Jones, Rachel B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937025/ https://www.ncbi.nlm.nih.gov/pubmed/33141217 http://dx.doi.org/10.1093/rheumatology/keaa541

Ejemplares similares

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
por: Tieu, Joanna, et al.
Publicado: (2021)

Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2018)

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
por: McClure, Mark E., et al.
Publicado: (2023)

Clinical Trials in Vasculitis
por: Gopaluni, Seerapani, et al.
Publicado: (2016)

Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)
por: Gopaluni, Seerapani, et al.
Publicado: (2022)

Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial
por: Gopaluni, Seerapani, et al.
Publicado: (2017)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Progress in treatment of ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2012)

Rituximab 500 mg 6-monthly infusions is an option in maintenance therapy of ANCA-associated vasculitis
por: Goel, Ruchika, et al.
Publicado: (2021)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis
por: McAdoo, Stephen P, et al.
Publicado: (2019)

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
por: Caroti, L., et al.
Publicado: (2019)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

High risk of stroke in ANCA-associated vasculitis—a population-based study
por: Tabakovic, Dennis, et al.
Publicado: (2022)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Salama, Alan D.
Publicado: (2019)

Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis
por: Yoo, Juyoung, et al.
Publicado: (2018)

ANCA Associated Vasculitis Subtypes: Response [Letter]
por: Merkel, Peter A, et al.
Publicado: (2022)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
por: Miyazaki, Yusuke, et al.
Publicado: (2020)

Predictors of relapses in ANCA-associated small vessel vasculitis with kidney involvement
por: Iuliana, Andreiana, et al.
Publicado: (2014)

The Sound of Interconnectivity; The European Vasculitis Society 2022 Report
por: Egan, Allyson C., et al.
Publicado: (2022)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study
por: Ysermans, Renée, et al.
Publicado: (2022)

Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab
por: Graham-Brown, M. P. M., et al.
Publicado: (2016)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
por: Harris, Claire, et al.
Publicado: (2018)

Early post-transplant recurrence of ANCA vasculitis while on belatacept maintenance immunosuppression
por: Agrawal, Amogh, et al.
Publicado: (2023)

ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia
por: Alahmari, Hana, et al.
Publicado: (2021)

The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset
por: Scott, Jennifer, et al.
Publicado: (2022)

The “4 plus 2” rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study
por: Roccatello, Dario, et al.
Publicado: (2017)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ruhcivtg8b6vktm8rd3jlvq6m8